Patent: 10,501,514
✉ Email this page to a colleague
Summary for Patent: 10,501,514
| Title: | Cyclic galanin-analogs and uses thereof |
| Abstract: | The invention generally relates to the field of medicine and pharmacology. More particularly, it relates to novel analogs of galanin, and the use thereof in therapy. Provided is a cyclic peptide analog of galanin, wherein the galanin analog comprises a (methyl)Lanthionine bridge and wherein the analog has the general formula “X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-”, or a truncated variant thereof lacking X1 and/or up to 11 of the C-terminal residues, wherein two residues selected from the group consisting of X3, X4, X6, X7, X10 and X13-X19 together form a Lanthionine bridge of the structure Ala-S-Ala, or a methyl Lanthionine bridge of the structure Abu-S-Ala or Ala-S-Abu. |
| Inventor(s): | Anneke Kuipers |
| Assignee: | LanthioPep BV |
| Application Number: | US15/557,273 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,501,514
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | ABRYSVO | respiratory syncytial virus vaccine | Injection | 125769 | May 31, 2023 | 10,501,514 | 2036-03-11 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,501,514
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016146513 | ⤷ Get Started Free |
| United States of America | 2020239536 | ⤷ Get Started Free |
| United States of America | 2018057556 | ⤷ Get Started Free |
| Russian Federation | 2727013 | ⤷ Get Started Free |
| Russian Federation | 2017133760 | ⤷ Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
